Joseph Han

Dr. Joseph Han

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 December 2022 in The Journal of Allergy and Clinical Immunology: In Practice
Verified
Journal Article
Closed access
SOShayan Owji
Shayan Owji
BUBenjamin Ungar
Benjamin Ungar
DDDanielle P. Dubin
Danielle P. Dubin
DPDina Michelle Poplausky
Dina Michelle Poplausky
JYJade N. Young
Jade N. Young
NGNicholas Gulati
Nicholas Gulati

15 July 2022 in The Journal of Rheumatology
Verified
Journal Article
Closed access
PDF file
MTMaria L. Taylor
Maria L. Taylor
KHKacie J. Hoyt
Kacie J. Hoyt
JHJoseph Han
Joseph Han
LBLeslie Benson
Leslie Benson
SCSiobhan Case
Siobhan Case
LHLauren A. Henderson
Lauren A. Henderson
Objective: To compare clinical outcomes in children with hemophagocytic lymphohistiocytosis (HLH) and macrophage activation syndrome (MAS) who were managed before and after implementation of an evidence-based guideline (EBG).Methods: A management algorithm for MAS-HLH was developed at our institution based on literature review, expert opinion, and consensus building across multiple pediatric subspecialties. An electronic medical record search retrospectively identified hospitalized patients with MAS-HLH in the pre-EBG (October 15, 2015, to December 4, 2017) and post-EBG (January 1, 2018, to January 21, 2020) time periods. Predetermined outcome metrics were evaluated in the 2 cohorts.Results: After the EBG launch, 57 children were identified by house staff as potential patients with MAS-HLH, and rheumatology was consulted for management. Ultimately, 17 patients were diagnosed with MAS-HLH by the treating team. Of these, 59% met HLH 2004 criteria, and 94% met 2016 classification criteria for MAS complicating systemic juvenile idiopathic arthritis. There was a statistically significant reduction in mortality from 50% before implementation of the EBG to 6% in the post-EBG cohort (P = 0.02). There was a significant improvement in time to 50% reduction in C-reactive protein level in the post-EBG vs pre-EBG cohorts (log-rank P < 0.01). There were trends toward faster time to MAS-HLH diagnosis, faster initiation of immunosuppressive therapy, shorter length of hospital stay, and more rapid normalization of MAS-HLH–related biomarkers in the patients post-EBG.Conclusion: While the observed improvements may be partially attributed to advances in treatment of MAS-HLH that have accumulated over time, this analysis also suggests that a multidisciplinary treatment pathway for MAS-HLH contributed meaningfully to favorable patient outcomes.

16 May 2022 in Experimental Dermatology
Verified
Journal Article
Closed access
MKMerav Koschitzky
Merav Koschitzky
KNKristina Navrazhina
Kristina Navrazhina
MGMichael S. Garshick
Michael S. Garshick
JGJuana Gonzalez
Juana Gonzalez
JHJoseph Han
Joseph Han
JKJames G. Krueger
James G. Krueger

8 November 2022 in JMIR Dermatology
Verified
Journal Article
Open access
AAAneesh Agarwal
Aneesh Agarwal
JHJoseph Han
Joseph Han
YLYen Luu
Yen Luu
NGNicholas Gulati
Nicholas Gulati
Background: Provider opt-out of accepting Medicare insurance is a nationally tracked metric by the Centers for Medicare & Medicaid Services (CMS) for all physicians, including dermatologists. Although this usually only consists of a small number of providers, the magnitude of opting out has varied historically, often tracing changes in systemic health care policy. Objective: In this paper, we explored dermatologist opt-out data since 2001, as reported by the CMS, to characterize trends and provide evidence that shifts in provider opt-out may represent a potential indicator of the state of health policy and possible needs for reform as it pertains to Medicare. Methods: The publicly available Opt Out Affidavits data set, available from the CMS, was evaluated for providers in all dermatologic specialties from January 1, 2001, to May 27, 2022. Results: There were a total of 196 dermatology opt-outs in the overall period, with the largest spike being 33 providers in 2016, followed by generally consistent decreases through 2021. In the most recent 12 months of data, the number of new monthly opt-outs from January 2022 to May 2022 was significantly higher than that of the trailing 7 months of 2021 (P=.03). Conclusions: Despite decreasing numbers of dermatologist opt-outs in the late-2010s, 2022 was marked by a significant increase in opt-outs. The reduced acceptance of Medicare by dermatologists may present risks to care access, so it is important to frequently assess physician opt-out data and changes over time.

6 May 2022 in SKIN The Journal of Cutaneous Medicine
Verified
Journal Article
Open access
PDF file
SOShayan Owji
Shayan Owji
JHJoseph Han
Joseph Han
HHHelen He
Helen He
ILIsabel Lopera
Isabel Lopera
MTMichael Tassavor
Michael Tassavor
JUJonathan Ungar
Jonathan Ungar
Introduction: Electrical impedance spectroscopy (EIS) is a non-invasive diagnostic device that measures the electrical impedance of skin lesions to assist in the detection of melanoma. While this tool has been shown to have a high sensitivity for melanoma diagnosis, data on its impact on clinical decision-making for pigmented skin lesions (PSLs) compared to other diagnostic tools is lacking. To gain further insight into its clinical utility, we conducted a pilot study to evaluate how this technology – specifically, the effect it has on clinical decisions for PSLs – compares to traditional dermoscopy. Methods: Dermatologists, dermatology residents, and medical students completed an online survey eliciting their biopsy decisions for 24 PSLs of varying histopathological diagnoses. Half of the lesions from each diagnosis group were presented as a clinical image with associated dermoscopic image and the other half as a clinical image with the corresponding EIS score. Results: Decisions made with EIS demonstrated a mean sensitivity of 75% for melanomas/severely dysplastic nevi vs. 66% for decisions made with dermoscopy (p=.008). While dermatologists biopsied with similar sensitivities when using EIS or dermoscopy (81% vs. 81%), residents and medical students biopsied with significantly greater sensitivity when using EIS. Respondents who reported rarely using dermoscopy showed the greatest improvement in sensitivity and specificity when using EIS compared to dermoscopy. Conclusion: Given that not all providers are trained in dermoscopy, and our finding that EIS particularly benefits those who infrequently use dermoscopy, EIS may complement dermoscopy by helping a broader range of providers make improved PSL diagnostic decisions.

27 April 2022 in JMIR Dermatology
Verified
Journal Article
Open access
JHJoseph Han
Joseph Han
SKSamir Kamat
Samir Kamat
AAAneesh Agarwal
Aneesh Agarwal
RORoss O'Hagan
Ross O'Hagan
CTConnor Tukel
Connor Tukel
NGNicholas Gulati
Nicholas Gulati